Active, not recruitingPHASE1, PHASE2NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Rapcabtagene autoleucel single agent(biological)
- Enrollment
- 217 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2019 – 2028
Study locations (30)
- University of California LA, Los Angeles, California, United States
- Stanford University Medical Center, Stanford, California, United States
- H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- Mass Gen Hosp Cancer Center, Boston, Massachusetts, United States
- University of Pennsylvania Clinical, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- St Davids South Austin Medical Ctr, Austin, Texas, United States
- Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Novartis Investigative Site, Melbourne, Victoria, Australia
- Novartis Investigative Site, Vienna, Austria
- Novartis Investigative Site, Marseille, France
- Novartis Investigative Site, Paris, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03960840 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn